GSK drug Seretide/Advair global revenue by region 2024

Revenue of GSK's Seretide/Advair worldwide from 2012 to 2024, by region (in million British pounds)

GSK: revenue of Seretide/Advair globally by region 2012-2024

Last update:

Mar 13, 2025

Author:

��ƽ�� Research Department

Regions:

Worldwide, United Kingdom

Survey time period:

From 01/01/2012 to 31/12/2024

This statistic depicts the global revenue of Seretide/Advair around the world from 2012 to 2024, by region. In 2024, Seretide/Advair generated a revenue of 364 million British pounds in the United States. Advair is the brand name marketed in the U.S. and Canada but is known as Seretide in many other countries. This pharmaceutical product is used to treat asthma through a combination of a preventer inhaler and a symptom controller.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Revenue of GSK's Seretide/Advair worldwide from 2012 to 2024, by region (in million British pounds)

Get in touch with us for additional information

��ƽ��